zidovudine has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (83.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, C; Liu, F; Ma, W; Yuan, L; Zhao, C | 1 |
| Moriyama, Y; Osman, Y; Shibata, A | 1 |
| Darnowski, JW; Ottaviani, E; Tosi, P; Tura, S; Visani, G | 1 |
| Cenacchi, A; Gamberi, B; Ottaviani, E; Tosi, P; Tura, S; Visani, G | 1 |
| Bernard, P; Cony-Makhoul, P; Leng, B; Mahon, FX; Nabera, CB; Pellegrin, JL; Reiffers, J | 1 |
| Blake, M; Chou, TC; Estrov, Z; Gutterman, JU; Kurzrock, R; Talpaz, M | 1 |
6 other study(ies) available for zidovudine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Emodin and AZT synergistically inhibit the proliferation and induce the apoptosis of leukemia K562 cells through the EGR1 and the Wnt/β‑catenin pathway.
Topics: beta Catenin; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Early Growth Response Protein 1; Emodin; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Wnt Signaling Pathway; Zidovudine | 2020 |
Enhanced elimination of Ph+ chromosome cells in vitro by combined hyperthermia and other drugs (AZT, IFN-alpha, TNF, and quercetin): its application to autologous bone marrow transplantation for CML.
Topics: Apoptosis; Bone Marrow Purging; Bone Marrow Transplantation; Drug Synergism; Hot Temperature; Humans; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Quercetin; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Zidovudine | 1995 |
Hydroxyurea enhances 3'-azido-3'-deoxythymidine (AZT) cytotoxicity in human chronic myeloid leukemia models.
Topics: Bone Marrow; Bone Marrow Cells; Cells, Cultured; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Drug Synergism; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Tumor Cells, Cultured; Zidovudine | 1994 |
Synergistic cytotoxicity of AZT plus alpha and gamma interferon in chronic myeloid leukemia cell line K562.
Topics: Cell Division; Cell Line; Cell Survival; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Synergism; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Recombinant Proteins; Thymidine; Tumor Cells, Cultured; Zidovudine | 1993 |
Improving the cytogenetic response to interferon alpha by zidovudine (AZT) in an HIV-positive chronic myelogenous leukemia patient.
Topics: Adult; Anti-HIV Agents; Antineoplastic Agents; Drug Therapy, Combination; Hematologic Tests; HIV Seropositivity; Humans; Interferon Type I; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Recombinant Proteins; Zidovudine | 1997 |
Synergistic antiproliferative effect of interferon alpha and azidothymidine in chronic myelogenous leukemia.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Synergism; Erythroid Precursor Cells; Female; Hematopoiesis; Hematopoietic Stem Cells; Humans; In Vitro Techniques; Interferon Type I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Zidovudine | 1991 |